The nation of Zimbabwe has rejected a major US healthcare agreement worth $367m (272 million pounds) over five years over Washington's request for confidential biological samples.
This move came to light following a government memo dated December was leaked, revealing that Head of State Emmerson Mnangagwa believed the deal was "unbalanced".
A government spokesman later clarified that the US was seeking health data for research and commercial gain but was not willing to share the resulting advantages from any future medical innovations.
"We will now turn to the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had provided over $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged further dialogue to find a agreement acceptable to both sides so the country's critical HIV treatment initiative can continue.
Wider Background
This development follows a similar situation in Kenya, where a court halted a similar deal with the US following concerns were filed about the security of Kenyans' health data.
Since resuming office last year, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the American government, but Trump stated its expenditure was "wasteful" and his administration was seeking government-to-government deals to enhance transparency and responsibility.
As per statements, 16 nations in Africa have so far agreed to similar agreements, representing over $18.3bn of fresh investment.
Details of the Declined Agreement
The money for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration might have yielded immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on antiretroviral therapy via American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"The proposal required Zimbabwe to surrender its genetic material and health information for a long time, with no equivalent guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"Put simply, our country would supply the raw materials for scientific discovery without any certainty that the final treatments would be available to our citizens if a future pandemic arise."
Sovereignty and Global Health
He also pointed out that the American exit from the global health body and its push of one-on-one deals were disrupting structures previously set up via the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to deal with future global health emergencies.
"This mechanism is intended to guarantee that when a nation contributes its data, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We encourage further discussions with our US partners on how future collaboration might be structured in a way that respects the sovereignty and dignity of both nations."
Health Experts Response
Medical experts expressed it acknowledged the government's concerns, but urged that talks need to persist since much of the nation's Aids initiatives were funded by international support.
"Where technical issues arise, such as those involving data governance or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," it commented.
This impasse underscores the ongoing tensions between accepting crucial international aid and safeguarding local interests in an ever more interconnected world.